BCM
BLUE

Bourgeon Capital Management’s bluebird bio BLUE Stock Holding History

Bourgeon Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-41
Closed -$24K – 256
2020
Q1 		$24K Buy
41
+24
+141% +$23.4K 0.01% 136
2019
Q4 		$20K Buy
+17
New +$18.5K 0.01% 151

Other funds holding BLUE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bourgeon Capital Management's BLUE Position: Q2 2020 in Review

Bourgeon Capital Management sold out of bluebird bio (BLUE) in Q2 2020, closing a stake of 41 shares — an estimated $24K sold.

Bourgeon Capital Management first reported a position in BLUE in Q4 2019 and held it in 2 quarters. The position peaked at $24K in Q1 2020. 278 funds tracked by Wall St. Rank hold BLUE as of Q2 2020.

  • Bourgeon Capital Management reported no remaining bluebird bio position as of Q2 2020 after selling out during the quarter.
  • Bourgeon Capital Management sold 41 bluebird bio shares in Q2 2020, an estimated $24K.
  • Bourgeon Capital Management first reported a position in bluebird bio in Q4 2019 and held it in 2 quarters.
  • Bourgeon Capital Management's bluebird bio position peaked at $24K in Q1 2020.
  • 278 funds tracked by Wall St. Rank held bluebird bio as of Q2 2020.

Based on Bourgeon Capital Management's 13F filing for Q2 2020, filed 27 Jul 2020.